PipelineReview.com - Biotech News & Online Store - Oglemilast, Glenmark's lead molecule for Asthma / COPD receives US FDA nod to initiate further Phase II trials

Oglemilast, Glenmark's lead molecule for Asthma / COPD receives US FDA nod to initiate further Phase II trials

30 Oct 2007

Glenmark Pharmaceuticals SA announced today that USFDA has provided a favorable partial response to the submission made by Forest, allowing it to initiate an additional Phase II study in COPD for Oglemilast (GRC 3886), Glenmark’s lead PDE4 inhibitor molecule

MUMBAI, India | October 29, 2007 | Glenmark Pharmaceuticals SA [GPSA], the wholly owned Swiss subsidiary of Glenmark

Pharmaceuticals Ltd. [Glenmark], announced today that USFDA has provided a favorable partial response to the submission made by Forest, allowing it to initiate an additional Phase II study in COPD for Oglemilast (GRC 3886), Glenmark’s lead PDE4 inhibitor molecule. The approval came after Forest satisfactorily addressed FDA’s outstanding non-clinical questions. Glenmark is working closely with Forest Labs, which is Glenmark’s North American partner for Oglemilast, to detail out plans for further longer term development, while additional communication is expected from the FDA in the next 2-3 months. Glenmark views this as an important positive step in continuing overall clinical development of Oglemilast

Speaking on this development, Mr. Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals Ltd., said, “The favourable response to Oglemilast from the FDA is an affirmation of Glenmark’s research capabilities and our focussed approach towards drug discovery. Today we have a pipeline of 11 lead molecules at various stages of development, with an increasing focus on NBE research along with NCE research. This progress reiterates Glenmark’s commitment towards setting benchmarks in speed, efficacy and monetisation of drug discovery & research.” GRC 3886 is a novel, orally available PDE4 inhibitor in development for Chronic Obstructive Pulmonary Disorder [COPD], and may also have utility in other conditions such as Asthma. According to the Centers for Disease Control, COPD affects approximately 24 million people in the United States and Asthma affects approximately 20 million. Combined, these markets are worth over $10 billion and are growing at a significant rate. PDE4 inhibitors target the underlying cause of both COPD and Asthma by blocking inflammation through a non-steroid dependent mechanism.

GPSA had entered into a collaborative agreement with Forest in September 2004, wherein Forest would develop, register and commercialize GRC 3886 for the North American market, while Glenmark will retain commercialization rights for the rest of the world. Forest paid Glenmark an up-front payment upon initiation of the agreement, and will pay other milestones if the development and commercialization of the product is successfully completed in the North American market; the total value of these payments could be $190 million. Additionally, after commercial launch, Glenmark will earn a royalty from Forest on net sales of the product, and, in addition, will supply all API for sale by Forest.

This was followed by a similar collaboration agreement with Teijin Pharma Limited for the territory of Japan in April 2005.

About Glenmark
Glenmark Pharmaceuticals Ltd. is a research-led, global, fully integrated pharmaceutical company headquartered in Mumbai, India. The Company is a leader in India in the discovery of new molecules. Glenmark has 11 lead molecules at various stages of development in NCE & NBE research. Three of the leads are in Phase II whereas eight other leads are into the pre-clinical and discovery stages in the broad areas of inflammation, metabolic disorders and oncology. The Company has generic formulation and API business interests in over 80 countries across the world including the highly regulated markets of USA and Europe. The formulation business spans several product segments such as Dermatology, Internal Medicine, Paediatrics, Gynaecology, ENT, Diabetes and Oncology. Glenmark’s first Asthma/COPD molecule, Oglemilast [GRC 3886], was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. The Company’s second lead GRC 8200, a DPP-IV inhibitor for Type II Diabetes was out-licensed to Merck KGaA, Germany for the North American, European and Japanese markets. A third molecule targeting pain, GRC 6211, is undergoing Phase II clinical trials in Europe.

SOURCE: Glenmark Pharmaceuticals SA

Search in our News Channels

Search in our Online Store